Margin resik Ascentage Pharma Corp (AAPG)

Ascentage Pharma (AAPG) - logo korporat

Unique apoptosis patents and massive R&D investments create a powerful defensive barrier for Ascentage Pharma Group (AAPG). Net profit returns from sales confirm this potential, where -229.30 serves as the current metric level. However, uncertainty regarding test outcomes and a shortage of funds create threats. Success depends on drug approvals in the US and China under strict FDA supervision.

AAPG: Rentabilitas resik perusahaan Ascentage Pharma Corp 25.01.2025 - 19.11.2026

Rincian metrik lan analitis perusahaan Ascentage (AAPG)

- rega saham lan prakiraan rega para ahli:
Analisis komprehensif perusahaan:Ascentage Pharma, AAPG
Barang unggulan Ascentage Pharma Group International

The scale of innovative cancer drug development led by Yan Dapin at Ascentage Pharma Group (AAPG) requires colossal expenditures, making net profit margin a key indicator of capital management efficiency. This metric is calculated as the share of final profit in total revenue, allowing investors to assess the business's ability to convert operational successes into real cash flow and confirm the asset's stability.

Karo sapa Ascentage Pharma Group saingan

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik CGON (CG Oncology Corp)|Margin resik UroGen Pharma (URGN)|Margin dodolan resik Bicara Therapeutics (BCAX)|Margin dodolan resik PSNL (personalis.com)|Tingkat bathi resik ERAS|DCTH: Rentabilitas dodolan miturut bathi resik|YmAbs - Rentabilitas resik perusahaan|aurabiosciences.com (AURA) - Margin resik|Candel Therapeutics Inc. - Tingkat bathi resik|Margin resik Accuray Inc.|Margin resik SELLAS Life Sciences Group SLS|Margin dodolan resik ACTU|CTOR - Margin resik|Margin dodolan resik HURA (TuHURA Biosciences, Inc.)|Tingkat bathi resik TARA|FATE: Rentabilitas dodolan miturut bathi resik|WHWK (aadibio.com) - Rentabilitas dodolan resik|TCRX (TScan Therapeutics, Inc.) - Rentabilitas dodolan miturut bathi resik|Margin resik Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Margin dodolan resik|CVM (CEL-SCI Corporation) - Rentabilitas resik perusahaan|Margin dodolan resik OSTX|Margin dodolan resik Radiopharm Theranostics Ltd (RADX)|Margin dodolan resik ARTV (Artiva Biotherapeutics)|Margin dodolan resik Adlai Nortye Ltd. ANL|Veru Inc - Margin dodolan resik|Margin dodolan perusahaan Tempest Therapeutics TPST|XLO: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)